NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

This study is testing a new type of engineered immune cell therapy called KD-496 CAR-T cells in people with advanced solid tumors like stomach cancer and pancreatic cancer. The CAR-T cells are designed to recognize and attack cancer cells that express two specific proteins (NKG2DL and CLDN18.2). **You may be eligible if...** - You are 18–75 years old - You have advanced solid cancer (such as gastric or pancreatic cancer) confirmed by biopsy - Standard treatments have failed or are not tolerated - Your cancer cells test positive for the target proteins (NKG2DL and/or CLDN18.2) - You are in reasonably good health (ECOG score 0–1) - You are expected to live at least 3 more months **You may NOT be eligible if...** - Your cancer tests negative for the required target proteins - You are too unwell to tolerate the treatment - You have certain blood, immune, or organ problems that make CAR-T therapy unsafe Talk to your doctor to see if this trial is right for you.